title: Cisapride decreasing orocecal transit time in patients with nonalcoholic steatohepatitis.
abstract: BACKGROUND
  Altered small-intestine motility, lengthening of orocecal transit time (OCTT), and small-intestinal bacterial overgrowth (SIBO) have been detected in patients with nonalcoholic steatohepatitis (NASH). These changes might be related to the progressive course and poor prognosis of the disease. This study was undertaken to investigate the effect of 4-week treatment with cisapride on OCTT.
  
  
  METHODS
  Ten NASH patients without diabetes were included. Ten healthy individuals served as controls. OCTT was measured by lactulose breath test (LBT). Anti-endotoxin core antibodies (EndoCAb) IgG were also examined. The effect of cisapride (10 mg TID during 4 weeks) on LBT and serum EndoCAb IgG levels in NASH patients was investigated.
  
  
  RESULTS
  The NASH patients had more significantly prolonged OCTT (95 +/- 17 min) than the controls (59 +/- 18 min, P=0.00032). Cisapride administration decreased OCTT (from 95 +/- 17 min to 83 +/- 19 min, P=0.037), basal breathed H2 (from 9.87 +/- 1.60 ppm to 8.61 +/- 1.63 ppm, P=0.046) and EndoCAb IgG titers (from 5.24 +/- 0.68 GMU/ml to 4.20 +/- 0.72 GMU/ml, P=0.013) in NASH patients.
  
  
  CONCLUSIONS
  The present data suggest the existence of deranged intestinal motility and endotoxemia in NASH patients. Cisapride administration during 4 weeks possibly restore intestinal motility and ameliorate endotoxemia in NASH patients.
authors.affiliation: Department of Gastroenterology, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China. fxs888@3126.com
authors.forename: Xiang-Sheng
authors.initials: XS
authors.lastname: Fu
authors.forename: Feng
authors.initials: F
authors.lastname: Jiang
mesh_terms: D020117:Cisapride / Q000494:pharmacology* / Q000627:therapeutic use; D019446:Endotoxemia / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D004731:Endotoxins / Q000276:immunology; D005234:Fatty Liver / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D005772:Gastrointestinal Transit / Q000187:drug effects*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged
chemical_list: D004731:Endotoxins; D005765:Gastrointestinal Agents; D007074:Immunoglobulin G; D020117:Cisapride